CLL & Lymphoma

The CLL & Lymphoma EU Focus Meeting 2026 will take place on March 13–14, 2026,

This educational meeting is designed to address ongoing learning needs in the management of chronic lymphocytic leukaemia and lymphoid malignancies, particularly in light of emerging clinical data, evolving treatment strategies, and their application in routine clinical practice. The programme theme, “Updating Knowledge & Clinical Practice in 2026,” reflects the objective of supporting evidence-based decision-making and improving patient care.

The meeting is intended for haematologists, oncologists, and other healthcare professionals involved in the diagnosis, treatment, and long-term management of patients with CLL and lymphoma.

The scientific programme will consist of expert-led presentations, moderated panel discussions, and structured roundtable sessions to facilitate peer-to-peer scientific exchange. All content is developed to be independent, balanced, and scientifically objective, based on current clinical evidence and guidelines, and free from promotional influence.

All faculty have been selected by the chairs of the meeting and have disclosed any relevant conflicts of interest.

Sponsors have had no influence on the programme content, speaker selection, or educational materials.

Chairs of CLL & Lymphoma EU Focus Meeting 2026:

Learning Objectives:

By the end of this meeting, participants should be able to:

1. Evaluate emerging clinical and biological data influencing current and future treatment strategies in CLL and major lymphoma subtypes, including LBCL, follicular lymphoma, mantle cell lymphoma, and T-cell lymphomas.

2. Assess mechanisms of treatment resistance and disease progression, including failure after CAR-T therapy, Richter transformation, and double-exposed or double-refractory CLL, and consider evidence-based management approaches.

3. Apply prognostic and predictive biomarkers (including molecular classification, cell of origin, and MRD assessment) to inform therapeutic decision-making across different disease stages and lines of therapy.

4. Compare front-line and subsequent treatment sequencing strategies, including continuous versus fixed-duration approaches, targeted therapies, immunochemotherapy, and transplant-based strategies, with consideration of long-term outcomes.

5. Discuss the role of novel and emerging therapies, such as bispecific antibodies, CAR-based approaches, non-covalent BTK inhibitors, BCL2 inhibitors, and new combination strategies in CLL and lymphoma.

6. Integrate evolving standards of care with patient-centred considerations, including treatment tolerability, disease biology, and real-world clinical scenarios, to optimise outcomes along the patient journey.